Reading the presentation, I was reminded of the Arrowhead Research concerning homing peptides:
http://www.arrowheadresearch.com/technology/homing-peptides
Delivery of canonical (and especially certain classes of non-canonical) siRNA is a very big business.
This could be an "market disruptive" development that PYC could exploit.
Silencing siRNA (over a protein class) could lead the way for targetted therapeutics for Phylomers (silencing over a protein "phase").
Hence there is potential for PYC to participate in markets around siRNA delivery - which is currently a very lucrative place to be.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.005(0.37%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.40 | $1.36 | $211.9K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4103 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 2028 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |